CA2412142A1 - A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes - Google Patents

A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes Download PDF

Info

Publication number
CA2412142A1
CA2412142A1 CA002412142A CA2412142A CA2412142A1 CA 2412142 A1 CA2412142 A1 CA 2412142A1 CA 002412142 A CA002412142 A CA 002412142A CA 2412142 A CA2412142 A CA 2412142A CA 2412142 A1 CA2412142 A1 CA 2412142A1
Authority
CA
Canada
Prior art keywords
alkyl
aryl
group
alicyclic
aralkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002412142A
Other languages
English (en)
French (fr)
Inventor
Paul D. Van Poelje
Mark D. Erion
Toshihiko Fujiwara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabasis Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2412142A1 publication Critical patent/CA2412142A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002412142A 2000-07-06 2001-07-05 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes Abandoned CA2412142A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06
US60/216,531 2000-07-06
PCT/US2001/021557 WO2002003978A2 (en) 2000-07-06 2001-07-05 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES

Publications (1)

Publication Number Publication Date
CA2412142A1 true CA2412142A1 (en) 2002-01-17

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002412142A Abandoned CA2412142A1 (en) 2000-07-06 2001-07-05 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes

Country Status (18)

Country Link
EP (1) EP1372660A2 (ru)
JP (1) JP2004508297A (ru)
KR (1) KR100854851B1 (ru)
CN (2) CN100396283C (ru)
AU (2) AU2001273271B2 (ru)
BR (1) BR0112212A (ru)
CA (1) CA2412142A1 (ru)
CZ (1) CZ20035A3 (ru)
HU (1) HUP0301830A3 (ru)
IL (2) IL153513A0 (ru)
MX (1) MXPA02012713A (ru)
NO (1) NO20030034L (ru)
NZ (1) NZ523227A (ru)
PL (1) PL365779A1 (ru)
RU (1) RU2328308C2 (ru)
SK (1) SK62003A3 (ru)
WO (1) WO2002003978A2 (ru)
ZA (1) ZA200300044B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
JP2002524463A (ja) 1998-09-09 2002-08-06 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規な芳香族インヒビター
AU2001245532B2 (en) 2000-03-08 2005-08-11 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-bisphosphatase inhibitors
NZ532427A (en) 2001-09-24 2008-07-31 Imp Innovations Ltd Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EA013249B1 (ru) 2003-12-26 2010-04-30 Киова Хакко Кирин Ко., Лтд. Производные тиазола
US20070225259A1 (en) * 2004-08-18 2007-09-27 Qun Dang Novel Thiazole Inhibitors of Fructose 1,6-Bishosphatase
TW200633720A (en) * 2004-12-13 2006-10-01 Sankyo Co Medicinal composition for diabetic
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (ja) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited 乾式製造法製剤
US20100222304A1 (en) 2006-11-02 2010-09-02 Lillian W Chiang Methods of Treating Neuropathic Pain by Modulation of Glycogenolysis or Glycolysis
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
UY35065A (es) * 2012-10-08 2014-05-30 Lg Life Sciences Ltd Fármaco combinado que comprende gemigliptina y metformina y método para su preparación
CN104788350A (zh) * 2014-01-22 2015-07-22 天津大学 一种通过快速冷却结晶法获得甲糖宁药用优势晶型的方法
CN106831437B (zh) * 2016-02-03 2019-06-21 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用
CN114907285B (zh) * 2021-02-10 2023-09-22 华中师范大学 酰化糖精类化合物及其制备方法和应用、降血糖药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2008325A1 (en) * 1989-01-24 1990-07-24 Harry E. Gruber Method and compounds for aica riboside delivery and for lowering blood glucose
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
PT970095E (pt) * 1997-03-07 2004-03-31 Metabasis Therapeutics Inc Novos inibidores benzimidazole de frutose-1,6-bisfosfatase
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU3087099A (en) * 1998-03-16 1999-10-11 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
JP2002524463A (ja) * 1998-09-09 2002-08-06 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規な芳香族インヒビター
CN101164618A (zh) * 1998-12-24 2008-04-23 症变治疗公司 治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合
PT1248604E (pt) * 2000-01-21 2007-01-31 Novartis Ag Associações compreendendo inibidor de dipeptidilpeptidase-iv
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Also Published As

Publication number Publication date
CN100396283C (zh) 2008-06-25
CN1599612A (zh) 2005-03-23
HUP0301830A2 (hu) 2003-11-28
BR0112212A (pt) 2003-12-30
IL153513A0 (en) 2003-07-06
NO20030034D0 (no) 2003-01-03
ZA200300044B (en) 2004-05-06
KR20030031952A (ko) 2003-04-23
RU2328308C2 (ru) 2008-07-10
AU7327101A (en) 2002-01-21
CZ20035A3 (cs) 2003-05-14
NO20030034L (no) 2003-03-05
PL365779A1 (en) 2005-01-10
WO2002003978A2 (en) 2002-01-17
WO2002003978A3 (en) 2003-10-16
NZ523227A (en) 2005-04-29
AU2001273271B2 (en) 2006-01-05
JP2004508297A (ja) 2004-03-18
SK62003A3 (en) 2003-09-11
HUP0301830A3 (en) 2007-10-29
EP1372660A2 (en) 2004-01-02
IL153513A (en) 2014-07-31
MXPA02012713A (es) 2004-09-10
KR100854851B1 (ko) 2008-08-27
CN101301294A (zh) 2008-11-12

Similar Documents

Publication Publication Date Title
US20090197836A1 (en) Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes
AU2001273271B2 (en) A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
AU771039B2 (en) A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
US20080004226A1 (en) Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes
AU2001273271A1 (en) A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
KR100818845B1 (ko) 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
CZ301401B6 (cs) Bisamidátfosfonátová predléciva a farmaceutické prostredky s jejich obsahem
AU2006201410A1 (en) A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1552850A2 (en) A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
MXPA01002542A (en) Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued